Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 493 to 502 of 502 entries
Sorted by: Best Match Show Resources per page
Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review.

OncoTargets and therapy

Imtiaz H, Khan M, Ehsan H, Wahab A, Rafae A, Khan AY, Jamil A, Sana MK, Jamal A, Ali TJ, Ansar I, Khan MM, Khouri J, Anwer F.
PMID: 34629878
Onco Targets Ther. 2021 Oct 01;14:4941-4960. doi: 10.2147/OTT.S317570. eCollection 2021.

Carfilzomib (CFZ) is a proteasome inhibitor currently approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Multiple trials are ongoing to evaluate its efficacy and safety in newly diagnosed multiple myeloma (NDMM). The use of CFZ-based two-...

Cite
Imtiaz H, Khan M, Ehsan H, et al. Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review. Onco Targets Ther. 2021;14:4941-4960doi: 10.2147/OTT.S317570.
Imtiaz, H., Khan, M., Ehsan, H., Wahab, A., Rafae, A., Khan, A. Y., Jamil, A., Sana, M. K., Jamal, A., Ali, T. J., Ansar, I., Khan, M. M., Khouri, J., & Anwer, F. (2021). Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review. OncoTargets and therapy, 144941-4960. https://doi.org/10.2147/OTT.S317570
Imtiaz, Hassaan, et al. "Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review." OncoTargets and therapy vol. 14 (2021): 4941-4960. doi: https://doi.org/10.2147/OTT.S317570
Imtiaz H, Khan M, Ehsan H, Wahab A, Rafae A, Khan AY, Jamil A, Sana MK, Jamal A, Ali TJ, Ansar I, Khan MM, Khouri J, Anwer F. Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review. Onco Targets Ther. 2021 Oct 01;14:4941-4960. doi: 10.2147/OTT.S317570. eCollection 2021. PMID: 34629878; PMCID: PMC8493667.
Copy Download .nbib Format: NLM
Immunotherapy of Multiple Myeloma: Promise and Challenges.

ImmunoTargets and therapy

Abramson HN.
PMID: 34527606
Immunotargets Ther. 2021 Sep 09;10:343-371. doi: 10.2147/ITT.S306103. eCollection 2021.

Whereas the treatment of MM was dependent solely on alkylating agents and corticosteroids during the prior three decades, the landscape of therapeutic measures to treat the disease began to expand enormously early in the current century. The introduction of...

Cite
Abramson HN. Immunotherapy of Multiple Myeloma: Promise and Challenges. Immunotargets Ther. 2021;10:343-371doi: 10.2147/ITT.S306103.
Abramson, H. N. (2021). Immunotherapy of Multiple Myeloma: Promise and Challenges. ImmunoTargets and therapy, 10343-371. https://doi.org/10.2147/ITT.S306103
Abramson, Hanley N. "Immunotherapy of Multiple Myeloma: Promise and Challenges." ImmunoTargets and therapy vol. 10 (2021): 343-371. doi: https://doi.org/10.2147/ITT.S306103
Abramson HN. Immunotherapy of Multiple Myeloma: Promise and Challenges. Immunotargets Ther. 2021 Sep 09;10:343-371. doi: 10.2147/ITT.S306103. eCollection 2021. PMID: 34527606; PMCID: PMC8437262.
Copy Download .nbib Format: NLM
Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data.

Pharmacological research

Cucchiara F, Ferraro S, Luci G, Bocci G.
PMID: 34785318
Pharmacol Res. 2021 Nov 14;175:105976. doi: 10.1016/j.phrs.2021.105976. Epub 2021 Nov 14.

Seizures are relatively common in cancer patients, and co-administration of chemotherapeutic and antiepileptic drugs (AEDs) is highly probable and necessary in many cases. Nonetheless, clinically relevant interactions between chemotherapeutic drugs and AEDs are rarely summarized and pharmacologically described. These...

Cite
Cucchiara F, Ferraro S, Luci G, et al. Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacol Res. 2021;175:105976doi: 10.1016/j.phrs.2021.105976.
Cucchiara, F., Ferraro, S., Luci, G., & Bocci, G. (2021). Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacological research, 175105976. https://doi.org/10.1016/j.phrs.2021.105976
Cucchiara, Federico, et al. "Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data." Pharmacological research vol. 175 (2021): 105976. doi: https://doi.org/10.1016/j.phrs.2021.105976
Cucchiara F, Ferraro S, Luci G, Bocci G. Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacol Res. 2021 Nov 14;175:105976. doi: 10.1016/j.phrs.2021.105976. Epub 2021 Nov 14. PMID: 34785318.
Copy Download .nbib Format: NLM
The numerical probability of carcinogenicity to humans of some pharmaceutical drugs: Alkylating agents, topoisomerase inhibitors or poisons, and DNA intercalators.

Fundamental & clinical pharmacology

Suarez-Torres JD, Orozco CA, Ciangherotti CE.
PMID: 33772863
Fundam Clin Pharmacol. 2021 Dec;35(6):1069-1089. doi: 10.1111/fcp.12674. Epub 2021 Apr 27.

The nonclinical branch of regulatory pharmacology has traditionally relied on the sensitivity and specificity of regulatorily recommended bioassays. Nonetheless, any predictive testing (eg, safety pharmacology) with less than 100% sensitivity or 100% specificity is prone to deliver false positive...

Cite
Suarez-Torres JD, Orozco CA, Ciangherotti CE. The numerical probability of carcinogenicity to humans of some pharmaceutical drugs: Alkylating agents, topoisomerase inhibitors or poisons, and DNA intercalators. Fundam Clin Pharmacol. 2021;35(6):1069-1089doi: 10.1111/fcp.12674.
Suarez-Torres, J. D., Orozco, C. A., & Ciangherotti, C. E. (2021). The numerical probability of carcinogenicity to humans of some pharmaceutical drugs: Alkylating agents, topoisomerase inhibitors or poisons, and DNA intercalators. Fundamental & clinical pharmacology, 35(6), 1069-1089. https://doi.org/10.1111/fcp.12674
Suarez-Torres, Jose D, et al. "The numerical probability of carcinogenicity to humans of some pharmaceutical drugs: Alkylating agents, topoisomerase inhibitors or poisons, and DNA intercalators." Fundamental & clinical pharmacology vol. 35,6 (2021): 1069-1089. doi: https://doi.org/10.1111/fcp.12674
Suarez-Torres JD, Orozco CA, Ciangherotti CE. The numerical probability of carcinogenicity to humans of some pharmaceutical drugs: Alkylating agents, topoisomerase inhibitors or poisons, and DNA intercalators. Fundam Clin Pharmacol. 2021 Dec;35(6):1069-1089. doi: 10.1111/fcp.12674. Epub 2021 Apr 27. PMID: 33772863.
Copy Download .nbib Format: NLM
Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data.

Pharmacological research

Cucchiara F, Ferraro S, Luci G, Bocci G.
PMID: 34785318
Pharmacol Res. 2021 Nov 14;175:105976. doi: 10.1016/j.phrs.2021.105976. Epub 2021 Nov 14.

Seizures are relatively common in cancer patients, and co-administration of chemotherapeutic and antiepileptic drugs (AEDs) is highly probable and necessary in many cases. Nonetheless, clinically relevant interactions between chemotherapeutic drugs and AEDs are rarely summarized and pharmacologically described. These...

Cite
Cucchiara F, Ferraro S, Luci G, et al. Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacol Res. 2021;175:105976doi: 10.1016/j.phrs.2021.105976.
Cucchiara, F., Ferraro, S., Luci, G., & Bocci, G. (2021). Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacological research, 175105976. https://doi.org/10.1016/j.phrs.2021.105976
Cucchiara, Federico, et al. "Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data." Pharmacological research vol. 175 (2021): 105976. doi: https://doi.org/10.1016/j.phrs.2021.105976
Cucchiara F, Ferraro S, Luci G, Bocci G. Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacol Res. 2021 Nov 14;175:105976. doi: 10.1016/j.phrs.2021.105976. Epub 2021 Nov 14. PMID: 34785318.
Copy Download .nbib Format: NLM
Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature.

Autoimmunity reviews

Pouchelon C, Visentini M, Emmi G, le Guern V, Quartuccio L, Samson M, Venhoff N, Briantais A, Casato M, Chatelus E, Chilles M, Cid MC, Diot E, Ebbo M, Faguer S, Hellmich B, Jachiet M, Moulinet T, Perrin F, Quémeneur T, Sinico RA, Terrier B.
PMID: 34995764
Autoimmun Rev. 2022 Jan 04;21(4):103034. doi: 10.1016/j.autrev.2022.103034. Epub 2022 Jan 04.

BACKGROUND: Glucocorticoids (GCs) plus rituximab (RTX) represent the first-line treatment of nonviral mixed cryoglobulinemia vasculitis (CryoVas). However, data on therapeutic management and outcome of patients refractory to RTX are lacking.METHODS: We conducted a European collaborative retrospective multicenter study of...

Cite
Pouchelon C, Visentini M, Emmi G, et al. Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. Autoimmun Rev. 2022;21(4):103034doi: 10.1016/j.autrev.2022.103034.
Pouchelon, C., Visentini, M., Emmi, G., le Guern, V., Quartuccio, L., Samson, M., Venhoff, N., Briantais, A., Casato, M., Chatelus, E., Chilles, M., Cid, M. C., Diot, E., Ebbo, M., Faguer, S., Hellmich, B., Jachiet, M., Moulinet, T., Perrin, F., Quémeneur, T., Sinico, R. A., & Terrier, B. (2022). Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. Autoimmunity reviews, 21(4), 103034. https://doi.org/10.1016/j.autrev.2022.103034
Pouchelon, Clara, et al. "Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature." Autoimmunity reviews vol. 21,4 (2022): 103034. doi: https://doi.org/10.1016/j.autrev.2022.103034
Pouchelon C, Visentini M, Emmi G, le Guern V, Quartuccio L, Samson M, Venhoff N, Briantais A, Casato M, Chatelus E, Chilles M, Cid MC, Diot E, Ebbo M, Faguer S, Hellmich B, Jachiet M, Moulinet T, Perrin F, Quémeneur T, Sinico RA, Terrier B. Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. Autoimmun Rev. 2022 Jan 04;21(4):103034. doi: 10.1016/j.autrev.2022.103034. Epub 2022 Jan 04. PMID: 34995764.
Copy Download .nbib Format: NLM
Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data.

Pharmacological research

Cucchiara F, Ferraro S, Luci G, Bocci G.
PMID: 34785318
Pharmacol Res. 2021 Nov 14;175:105976. doi: 10.1016/j.phrs.2021.105976. Epub 2021 Nov 14.

Seizures are relatively common in cancer patients, and co-administration of chemotherapeutic and antiepileptic drugs (AEDs) is highly probable and necessary in many cases. Nonetheless, clinically relevant interactions between chemotherapeutic drugs and AEDs are rarely summarized and pharmacologically described. These...

Cite
Cucchiara F, Ferraro S, Luci G, et al. Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacol Res. 2021;175:105976doi: 10.1016/j.phrs.2021.105976.
Cucchiara, F., Ferraro, S., Luci, G., & Bocci, G. (2021). Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacological research, 175105976. https://doi.org/10.1016/j.phrs.2021.105976
Cucchiara, Federico, et al. "Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data." Pharmacological research vol. 175 (2021): 105976. doi: https://doi.org/10.1016/j.phrs.2021.105976
Cucchiara F, Ferraro S, Luci G, Bocci G. Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacol Res. 2021 Nov 14;175:105976. doi: 10.1016/j.phrs.2021.105976. Epub 2021 Nov 14. PMID: 34785318.
Copy Download .nbib Format: NLM
The Association of Mitochondrial Copy Number With Sarcopenia in Adult Survivors of Childhood Cancer.

Journal of the National Cancer Institute

McCastlain K, Howell CR, Welsh CE, Wang Z, Wilson CL, Mulder HL, Easton J, Mertens AC, Zhang J, Yasui Y, Hudson MM, Robison LL, Kundu M, Ness KK.
PMID: 33871611
J Natl Cancer Inst. 2021 Nov 02;113(11):1570-1580. doi: 10.1093/jnci/djab084.

BACKGROUND: Adult childhood cancer survivors are at risk for frailty, including low muscle mass and weakness (sarcopenia). Using peripheral blood mitochondrial DNA copy number (mtDNAcn) as a proxy for functional mitochondria, this study describes cross-sectional associations between mtDNAcn and...

Cite
McCastlain K, Howell CR, Welsh CE, et al. The Association of Mitochondrial Copy Number With Sarcopenia in Adult Survivors of Childhood Cancer. J Natl Cancer Inst. 2021;113(11):1570-1580doi: 10.1093/jnci/djab084.
McCastlain, K., Howell, C. R., Welsh, C. E., Wang, Z., Wilson, C. L., Mulder, H. L., Easton, J., Mertens, A. C., Zhang, J., Yasui, Y., Hudson, M. M., Robison, L. L., Kundu, M., & Ness, K. K. (2021). The Association of Mitochondrial Copy Number With Sarcopenia in Adult Survivors of Childhood Cancer. Journal of the National Cancer Institute, 113(11), 1570-1580. https://doi.org/10.1093/jnci/djab084
McCastlain, Kelly, et al. "The Association of Mitochondrial Copy Number With Sarcopenia in Adult Survivors of Childhood Cancer." Journal of the National Cancer Institute vol. 113,11 (2021): 1570-1580. doi: https://doi.org/10.1093/jnci/djab084
McCastlain K, Howell CR, Welsh CE, Wang Z, Wilson CL, Mulder HL, Easton J, Mertens AC, Zhang J, Yasui Y, Hudson MM, Robison LL, Kundu M, Ness KK. The Association of Mitochondrial Copy Number With Sarcopenia in Adult Survivors of Childhood Cancer. J Natl Cancer Inst. 2021 Nov 02;113(11):1570-1580. doi: 10.1093/jnci/djab084. PMID: 33871611; PMCID: PMC8562958.
Copy Download .nbib Format: NLM
The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices.

Frontiers in neuroscience

Di Cintio F, Dal Bo M, Baboci L, De Mattia E, Polano M, Toffoli G.
PMID: 33324155
Front Neurosci. 2020 Nov 25;14:603647. doi: 10.3389/fnins.2020.603647. eCollection 2020.

Glioblastoma (GBM) is the most frequent and aggressive primary central nervous system tumor. Surgery followed by radiotherapy and chemotherapy with alkylating agents constitutes standard first-line treatment of GBM. Complete resection of the GBM tumors is generally not possible given...

Cite
Di Cintio F, Dal Bo M, Baboci L, et al. The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices. Front Neurosci. 2020;14:603647doi: 10.3389/fnins.2020.603647.
Di Cintio, F., Dal Bo, M., Baboci, L., De Mattia, E., Polano, M., & Toffoli, G. (2020). The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices. Frontiers in neuroscience, 14603647. https://doi.org/10.3389/fnins.2020.603647
Di Cintio, Federica, et al. "The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices." Frontiers in neuroscience vol. 14 (2020): 603647. doi: https://doi.org/10.3389/fnins.2020.603647
Di Cintio F, Dal Bo M, Baboci L, De Mattia E, Polano M, Toffoli G. The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices. Front Neurosci. 2020 Nov 25;14:603647. doi: 10.3389/fnins.2020.603647. eCollection 2020. PMID: 33324155; PMCID: PMC7724040.
Copy Download .nbib Format: NLM
Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data.

Pharmacological research

Cucchiara F, Ferraro S, Luci G, Bocci G.
PMID: 34785318
Pharmacol Res. 2022 Jan;175:105976. doi: 10.1016/j.phrs.2021.105976. Epub 2021 Nov 14.

Seizures are relatively common in cancer patients, and co-administration of chemotherapeutic and antiepileptic drugs (AEDs) is highly probable and necessary in many cases. Nonetheless, clinically relevant interactions between chemotherapeutic drugs and AEDs are rarely summarized and pharmacologically described. These...

Cite
Cucchiara F, Ferraro S, Luci G, et al. Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacol Res. 2021;175:105976doi: 10.1016/j.phrs.2021.105976.
Cucchiara, F., Ferraro, S., Luci, G., & Bocci, G. (2022). Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacological research, 175105976. https://doi.org/10.1016/j.phrs.2021.105976
Cucchiara, Federico, et al. "Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data." Pharmacological research vol. 175 (2022): 105976. doi: https://doi.org/10.1016/j.phrs.2021.105976
Cucchiara F, Ferraro S, Luci G, Bocci G. Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacol Res. 2022 Jan;175:105976. doi: 10.1016/j.phrs.2021.105976. Epub 2021 Nov 14. PMID: 34785318.
Copy Download .nbib Format: NLM
Showing 493 to 502 of 502 entries